je.st
news
Tag: pharma
Auxilium Pharma rejects Endo's takeover offer
2014-09-22 15:41:55| Biotech - Topix.net
Auxilium Pharmaceuticals Inc.'s board has rejected an approximately $1.4 billion unsolicited takeover offer from Ireland's Endo International PLC. Auxilium, based in Chesterbrook, Pennsylvania, had adopted a one-year "poison pill" shareholder rights plan last week.
Tags: offer
pharma
rejects
takeover
Nobel prizes and the world's top drug: a gallery of Scottish pharma
2014-09-17 23:45:35| Food - Topix.net
On the eve of the historical vote on Scottish independence from the UK tomorrow, we take a look at the pharma inventions Scotland gave the world. Whether you're in the "yes" or "no" camp, it's undeniable that Scotland's discoveries have changed the course of medicine, and that its present-day pharma industry - which includes sites operated by GSK, J&J and Merck & Co.
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab
2014-09-17 14:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J., and MUMBAI, India WHITEHOUSE STATION, N.J., and MUMBAI, India--(BUSINESS WIRE)--Merck & Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, and Sun Pharmaceutical Industries Ltd. Language: English Contact: MerckMedia:Ian McConnell, 908- 423-3046Investor:Justin Holko, 908-423-5088orSun PharmaMedia:Frederick Castro, +91-22-66455964Investor:Nimish Desai, +91-22-66455717 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: 524715 Exchange: MUMBAI read more
Moberg Pharma announces successful results for MOB-015 in a Phase II...
2014-09-17 10:42:21| Appliances - Topix.net
Moberg Pharma AB announces successful top-line results from a phase II study for MOB-015 in onychomycosis . The primary endpoint, mycological cure after 15 months, was achieved in 54% of the patients.
Tags: results
ii
successful
phase
Endo Int'l makes $1.4B offer for Auxilium Pharma
2014-09-17 02:31:59| Biotech - Topix.net
Endo International PLC says it is making an unsolicited offer for Auxilium Pharmaceuticals that values Auxilium at $28.10 per share. The deal is worth $1.41 billion in cash and stock, based on Auxilium's shares outstanding.
Sites : [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] next »